Product Details
| Product Name:
Talacotuzumab |
CAS No.:
1826831-79-1 |
| Purity:
98.42% (SEC-HPLC) |
Supply Ability:
10g |
| Release date:
2025/05/05 |
Product Introduction
Bioactivity
| Name | Talacotuzumab |
| Description | Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affinity for CD123, CD32b/c, CD16-158F and CD16-158V, with KD of 0.43 nM, 188 nM, 46 nM and 16.8 nM, respectively. Talacotuzumab inhibits IL-3 signaling in target cells by inhibiting IL-3 binding to CD123. Talacotuzumab induces mutations in the Fc region to increase affinity for CD16 (FCγriiia), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab inhibits leukemia cell growth in xenografted mouse models of acute myeloid leukemia (AML). |
| In vitro | With an IC50 of 5 ng/ml (33 pM), Talacotuzumab (JNJ 56022473; CSL 362) potently mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in TF-1 cells [1].
Following a 24-hour pretreatment at 1 μg/ml,Talacotuzumab inhibits the production of IFN-α in plasmacytoid dendritic cells and eosinophils in SLE (systemic lupus erythematosus) donor and healthy donor plasma-like dendritic cells. This inhibition occurs when these cells are stimulated with TLR7 (imiquimod; 0.5 μM; 6 days) and TLR9 (CpG C; 0.5 μM; 6 days). However, Talacotuzumab does not significantly reduce IFN-α production induced by TLR4 stimulation (LPS; 10 μg/ml). The inhibitory effect of Talacotuzumab on plasmacytoid dendritic cell (pDC) proliferation and expansion induced by TLR7 and TLR9 is achieved through the depletion of pDC [2]. |
| In vivo | In mice with xenografts of acute myeloid leukemia,Talacotuzumab (JNJ 56022473; CSL 362; 300 μg; intraperitoneal injection; three times per week for 5 weeks) significantly delays tumor growth compared to the isotype control [1].
Talacotuzumab (1, 10, 30 mg/kg; subcutaneous injection; single dose) in juvenile cynomolgus monkeys reaches maximum serum concentrations of 12, 190, and 380 μg/ml at doses of 1, 10, and 30 mg/kg, respectively, within 48 hours [2]. |
| Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
| Keywords | Talacotuzumab | JNJ-56022473 | JNJ56022473 | Interleukin Related | Inflammationrelated | Inflammation related | Immunologyrelated | Immunology related | CSL-362 | CSL362 | CD123 |
| Inhibitors Related | Sodium Thiocyanate | Disulfiram | Benzyl cinnamate | Deucravacitinib | Apilimod mesylate | Pirazolac | SMA-12b | Hydrocortisone hemisuccinate | beta-Escin | Muscone | Balsalazide disodium dihydrate | Apilimod |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1648843-04-2
$34.00 / 1mg
-
CAS:4673-26-1
$38.00 / 5mg
-
CAS:2162134-62-3
$313.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States